This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Appfolio is expanding in Goleta. Appfolio will lease an additional 7,855 square feet of space at its office at 50 Castilian Drive in Goleta, according to documents filed with the Securities and Exchange Commission on Oct. 14. The new space will increase the amount of space Appfolio leases from Nassau Land Company to 26,490 square Read More →
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
One of the world’s most expensive cancer drugs got conditional approval from European regulators on Sept. 25. Europeans granted Thousand Oaks-based Amgen conditional approval of its rare blood cancer drug Blincyto and gave a positive evaluation of Amgen’s multiple-myeloma drug Kyprolis. Blincyto is an immunotherapy that is designed to treat a rare form of leukemia Read More →
By Philip Joens / Friday, September 25th, 2015 / Technology, Top Stories / Comments Off on Industry titans ponder future of digital music
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Pharmaceuticals Amgen and Allergan announced positive Phase 3 study results of their new drug ABP 215 on Sept. 23. The drug, used to treat lung cancer, is being developed as a biosimilar to Roche Holding AG’s Avastin. ABP 215 showed clinical safety and effectiveness compared to Avastin. “Lung cancer is the leading cause of cancer Read More →